Survival Rate for Rare Form of Bone Cancer Improving

Share this content:

the Cancer Therapy Advisor take:

The survival rate for mesenchymal chondrosarcoma, a rare form of cancer found in young adults that begins in bone cartilage, is not as dismal as previously reported, according to research out of Loyola University Medical Center.

At the recent Mid-America Orthopedic Association annual meeting in South Carolina, researchers led by Lukas Nystrom, MD, presented findings that looked at 205 cases of mesenchymal chondrosarcoma from 1973 to 2011. Data was taken from the SEER program database administered through the National Cancer Institute.

They found that 51 percent of these patients survived at least five years, and 43 percent at least 10 years.

In addition, survival rates depended on where tumors were located. Those with tumors on the spine, pelvis or trunk, for instance, were found to have worse outcomes than those with tumors in the arms or legs. Dr. Nystrom stated that this is likely due to tumors being located in inoperable areas.

Overall improvement in survival was likely due to improved CT and MRI imaging, as well as the chemotherapy administration in the treatment regimen.

Research indicates the addition of the time from prostatectomy to radiation therapy was not signific
Survival rate for mesenchymal chondrosarcoma, a rare form of cancer, is not as dismal as previously reported.
Ten-year survival of a rare malignancy called mesenchymal chondrosarcoma has been reported to be as low as 20 percent, but a Loyola study has found survival is not as dismal as prior reports.
READ FULL ARTICLE From Newswise

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters